The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Treatment results of the tagraxofusp cohort of the BPDCN international registry
Astghik Voskanyan, MD, Immune Oncology Research Institute (IMMONC), Yerevan, Armenia, outlines the outcomes of the tagraxofusp cohort of the blastic plasmacytoid dendritic cell neoplasm (BPDCN) international registry. In 22 patients receiving treatment with tagraxofusp, a targeted therapy against CD123, the response rate was 82%, with nine patients achieving a complete response (CR). Dr Voskanyan emphasizes the need for further data collection to identify new treatment directions for this rare and challenging disease. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
I would like to present at first our registry very shortly. Our registry was launched in 2022 and by July 24, we have collected 70 patients, and from these patients, only 22 patients have received treatment with tagraxofusp, which is the new targeted therapy against CD123. Although this is a very effective medicine for these patients, the relapse rate remains high, and most patients without allogeneic transplantation relapse...
I would like to present at first our registry very shortly. Our registry was launched in 2022 and by July 24, we have collected 70 patients, and from these patients, only 22 patients have received treatment with tagraxofusp, which is the new targeted therapy against CD123. Although this is a very effective medicine for these patients, the relapse rate remains high, and most patients without allogeneic transplantation relapse.
In our cohort, the majority of patients, 17 patients, received tagraxofusp as a first-line therapy, and the other five patients received it as a second-line therapy. And the majority of patients, about 82% of patients, developed a response. Overall, the response rate was 82%, from which nine patients have a complete response, and the other patients have stable disease or partial remission.
The problem is this disease is very rare, and there is no consensus on the treatment of this disease, and our aim is to collect as much data as possible to find out new treatment directions because most of the patients are elderly patients, and they are not eligible for autologous transplantation, and without transplantation, they relapse, and the results are not satisfying, and we are going to collect more and more data and to develop maybe new directions of treatment.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
